Paul Tudor Jones’s Dianthus Therapeutics DNTH Stock Holding History

Paul Tudor Jones’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.64M	Buy	+37,308	New	+$3.26M	0.01%	1508
2020 Q4	–	Sell	-1,842	Closed	-$200K	–	1386
2020 Q3	$200K	Sell	1,842 -296	-14%	-$35.1K	0.01%	1137
2020 Q2	$257K	Buy	+2,138	New	+$301K	0.01%	929
2018 Q3	–	Sell	-625	Closed	-$135K	–	1115
2018 Q2	$135K	Buy	+625	New	+$141K	﹤0.01%	966

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Paul Tudor Jones's DNTH Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 37,308 shares worth $3.64M. The stake represents 0.01% of the portfolio and ranks #1508 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in DNTH as recently as Q3 2020.

Paul Tudor Jones first reported a position in DNTH in Q2 2018 and has held it in 4 quarters since. 267 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Paul Tudor Jones held 37,308 shares of Dianthus Therapeutics worth $3.64M as of Q2 2026.
Dianthus Therapeutics was a new Paul Tudor Jones position in Q2 2026.
Dianthus Therapeutics made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1508 holding.
Paul Tudor Jones first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 4 quarters since.
267 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.